Search
Quinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnQuinagolide is currently available in several countries including Canada, but not approved for treatment in the United States. … These drugs are effective in patients who are intolerant or resistant to [DB01200].
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative … [L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant]
Ferumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigationalIn January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns. … high dose by rapid intravenous injection [L2181].
Terpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawnElixirs of terpin hydrate are still available to patients as prescription medications to be prepared by specialty compounding pharmacies. … It was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate
Pancrelipase amylase
go.drugbank.com/drugs/DB11065ApprovedInvestigational[L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. … [T177] The pancrelipase amylase is a single polypeptide chain containing two SH groups and four disulfide bridges.
Febuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigational[L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones … The manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51329] CLN2 is a predominantly pediatric-onset neurodegenerative disease caused by a deficiency in the lysosomal enzyme TPP1, leading to progressive impairment in motor and cognitive function. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]
Dementia With Lewy Body Disease
go.drugbank.com/conditions/DBCOND0077924Synonyms: Late onset dementia due to Lewy body disease (disorder)Head Injury
go.drugbank.com/conditions/DBCOND0028168Drugs: CerebrolysinSynonyms: [X]Injuries to the head (disorder)Hospital-Acquired Pneumonia
go.drugbank.com/conditions/DBCOND0038730Synonyms: Pneumonia due to bacteria NOS (disorder)